News on research and diagnostics for metabolic disorders and metabolic diseases.
An analysis of 3,000 subjects found the test could identify diabetes patients at risk of developing chronic kidney disease within the next four years.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.
Luminist Labs is developing diagnostic technology for liver disease, which DiscernDx will integrate into its precision medicine platform.
The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease.
